Comprehensive Medical Weight Loss Denver
Eli Lilly’s retatrutide just got more interesting. Two new Phase 3 trials—TRIUMPH-2 and TRIUMPH-3—delivered results that matter for the patients I see most: people with obesity complicated by type 2 diabetes or established cardiovascular disease. The triple GIP/GLP-1/glucagon agonist achieved…
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | July 30, 2026 — The way American teenagers are getting treated for obesity has changed more in the last three years than in the previous three decades. A…
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | August 3, 2026 The obesity medicine pipeline just got more interesting. Three weeks ago, Eli Lilly released topline results from two additional Phase 3 trials of retatrutide —…
The wait is over. The SURMOUNT-5 trial results are in, and they answer the question my patients ask me every week: “Which one is better?” For tirzepatide (Zepbound) and semaglutide (Wegovy), the full dataset published in The New England Journal…
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | July 24, 2026 If you got your GLP-1 prescription through a telehealth app and pay $50 a month, you may want to read this carefully. The FDA just…
The Reality of Muscle Loss on Anti-Obesity Medications: What the Data Actually Shows When you lose 30, 50, or 100 pounds, you are not just losing fat—you are also shedding lean mass. It is a predictable physiological reality of significant…
The Short Version A new kind of GLP-1 pill is showing real weight-loss results — and it isn’t a peptide. Aleniglipron (Structure Therapeutics, GSBR-1290) is a small molecule you swallow once a day, with no refrigeration, no injection, and no…
There’s a quiet assumption many patients bring to a GLP-1 prescription: the weight comes off, the body gets lighter, and movement gets easier. Wearable data presented at ENDO 2026 on June 13 says the opposite. Adults with obesity who started…
There’s a moment in every obesity medicine career when a drug does something unexpected. At this year’s American Diabetes Association Scientific Sessions in New Orleans, survodutide did several unexpected things at once. The dual GLP-1/glucagon receptor agonist — developed by…
Here’s something I hear constantly from patients: “I can handle the side effects, but the every-week injection is what wears me down.” It’s a real barrier — and honestly, one of the main reasons people fall off GLP-1 therapy. Pfizer…
